The positive Phase 2b data significantly de-risks the VCN-01 program and strengthens the company's position for partnerships, funding, or a potential acquisition. Traders should monitor for updates on the planned Phase 3 trial and any subsequent partnership announcements.
Price Chart
Executive Summary
Theriva Biologics announced positive results from its VIRAGE Phase 2b clinical trial, showing improved overall survival and progression-free survival in metastatic pancreatic cancer patients treated with VCN-01 plus chemotherapy. The data, to be presented at the AACR 2026 meeting, supports an immune-mediated mechanism of action and demonstrates consistent benefits across subgroups, including those with liver metastases.
Key Facts
- Patients receiving VCN-01 + chemotherapy had improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
- The survival benefit was maintained across subgroups, including patients with liver metastases.
- Patients who received a second dose of VCN-01 showed a greater benefit in OS and PFS.
- The company has achieved alignment with both the FDA and EMA on a proposed pivotal Phase 3 trial.
- The data presentation is scheduled for the AACR Annual Meeting on April 20, 2026.
Financial Impact
No direct financial figures provided, but the positive clinical data significantly increases the potential value of the VCN-01 program.
Risk Factors
- The data is from a Phase 2b trial and must be confirmed in a larger, pivotal Phase 3 study.
- The company is small (market cap $12M) and may face challenges in funding and executing the Phase 3 trial without a partnership.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-044906 |
| Document: tm2612012d1_ex99-1.htm | 0001104659-26-044906 |
| Document: tm2612012d1_ex99-2.htm | 0001104659-26-044906 |
| Document: 0001104659-26-044906-index-headers.html | 0001104659-26-044906 |
| Document: 0001104659-26-044906-index.html | 0001104659-26-044906 |
| Document: 0001104659-26-044906.txt | 0001104659-26-044906 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 11, 2026 7w ago | Press Release | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 4, 2026 8w ago | 8-K | $0.2300 $0.2490 | ▼ −8.26% | ▼ −9.50% | $0.2306 (−0.26%) |
Jul 7, 2026 12w ago | 8-K | $0.2354 $0.2227 | ▼ −5.40% | ▼ −6.73% | $0.2306 (−2.04%) |
Jun 11, 2026 16w ago | Press Release | $0.3070 $0.2345 | ▼ −23.62% | ▼ −25.51% | $0.2306 (−24.89%) |
Apr 17, 2026 23w ago | 8-K | $0.4100 $0.3000 | ▼ −26.83% | ▼ −31.03% | $0.2306 (−43.76%) |
Mar 12, 2026 29w ago | 8-K | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
Mar 12, 2026 29w ago | Press Release | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access